Acadia Pharmaceuticals Inc.

Allergan, Inc.

A. Carlsson Research Ab

Ethan S Burstein

Roger Olsson

Karl Erik Jansson

Niklas Patrik Sköld

Henrik Von Wachenfeldt

Björn Gustav Borgström

Larisa Yudina Wahlström

Fabrice Piu

Mark R Brann

David M Weiner

Jorgen Eskildsen

Jakob L Hansen

Andria Lee

Magnus Gustav Wilhelm Bergner

Lizzie Maria Carlsson

Angélica Kloberg

Per Arvid Emil Carlsson

The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

Compounds, salts thereof and methods for treatment of diseases

The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.

A method for treating a impulse control disorder in a patient comprising administering to the patient an effective amount of pimavanserin or a pharmaceutical acceptable salt thereof.

Pimavanserin for treating impulse control disorder

Compounds of formula (I) and methods are provided for the treatment of disease or conditions in which modification of cholinergic, especially muscarinic receptor activity, has a beneficial effect. 

Muscarinic agonists

The invention provides compositions and methods for screening individuals for the presence of G-protein coupled receptor (GPCR) variants. The compositions and methods are useful for determining clinical outcome of drug therapy or for tailoring drug therapy for the individual based upon the presence or absence of one or more GPCR variants in the subject.

Clinical indications for genotyping polymorphic variants of G-protein coupled receptors

Growing community of inventors

San Diego, CA, United States of America

Ethan S Burstein